Veeral Ajmera
University of California, San Diego
H-index: 29
North America-United States
Top articles of Veeral Ajmera
Rise of the Machines: The Utilization of Technology for Triple-Organ Transplantation
The Journal of Heart and Lung Transplantation
2024/4/1
New developments in biomarkers and clinical drug development in alpha‐1 antitrypsin deficiency‐related liver disease
2024/3/22
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States
Alimentary Pharmacology & Therapeutics
2024/3
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality
Alimentary pharmacology & therapeutics
2024/1
Veeral Ajmera
H-Index: 16
NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates
Clinical Gastroenterology and Hepatology
2024/1/1
Cheng Han Ng
H-Index: 5
Nicholas Syn
H-Index: 20
Mark Muthiah
H-Index: 5
Veeral Ajmera
H-Index: 16
Philip Vutien
H-Index: 10
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes
Hepatology
2024/5/1
Veeral Ajmera
H-Index: 16
A prospective study on the prevalence of at‐risk MASH in patients with type 2 diabetes mellitus in the United States
Alimentary Pharmacology & Therapeutics
2024/4/8
Veeral Ajmera
H-Index: 16
Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
Alimentary Pharmacology & Therapeutics
2024/4/3
Ramazan Idilman
H-Index: 27
Veeral Ajmera
H-Index: 16
Sa1566 NATURAL HISTORY OF HEPATIC DECOMPENSATION AND LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Gastroenterology
2023/5/1
254 ACHIEVING MORE EQUITABLE ALLOCATION OF DONOR LIVER GRAFTS THROUGH BALANCING SURVIVAL AND MEDICAL URGENCY: A NOVEL MATHEMATICAL MODEL MONALISA 1.0
Gastroenterology
2023/5/1
109 VALIDATION OF THE AGA CLINICAL CARE PATHWAY AND NEW AASLD GUIDANCE FOR NONALCOHOLIC FATTY LIVER DISEASE IN A PROSPECTIVE COHORT OF PATIENTS WITH TYPE 2 DIABETES
Gastroenterology
2023/5/1
Sa1542 OUTCOMES AND SURVIVAL OF ALPHA 1 ANTITRYPSIN DEFICIENCY IN LIVER TRANSPLANTATION
2023/5/1
Sa1553 HEPATIC DECOMPENSATION AND HEPATOCELLULAR CARCINOMA RISK IN NONALCOHOLIC FATTY LIVER DISEASE AMONG PATIENTS WITH DIABETES VERSUS PATIENTS WITHOUT DIABETES: SYSTEMATIC …
2023/5/1
Advances in the genetics of nonalcoholic fatty liver disease
2023/5/1
Veeral Ajmera
H-Index: 16
Reply to:“Screening for NAFLD and its severity in type 2 diabetic patients: Value of magnetic resonance imaging and outstanding issues”
Journal of Hepatology
2023/5/1
Veeral Ajmera
H-Index: 16
“being normal weight each day keeps NAFLD and fibrosis away”—the importance of reducing cumulative exposure to overweight. Authors' reply
2023/5
Veeral Ajmera
H-Index: 16
Longitudinal association between overweight years, polygenic risk and NAFLD, significant fibrosis and cirrhosis
Alimentary Pharmacology & Therapeutics
2023/5
HTA2 Cost-Effectiveness of a Clinical Care Pathway for the Screening of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus
Value in Health
2023/12/1
Towards omics-based risk assessment in NAFLD
Nature Metabolism
2023/4
Veeral Ajmera
H-Index: 16
Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study
JHEP Reports
2023/4/1
